Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial

Objective To investigate the long‐term weight loss outcomes during usual clinical practice after switching from olanzapine standard oral tablet (SOT) to olanzapine orally disintegrating tablets (ODT). Method In this open‐label prospective study, 26 patients with schizophrenia who were clinically sta...

Full description

Saved in:
Bibliographic Details
Published in:Human psychopharmacology 2008-04, Vol.23 (3), p.211-216
Main Authors: Chawla, Bharat, Luxton-Andrew, Heather
Format: Article
Language:English
Subjects:
Adult
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Benzodiazepines - administration & dosage
Benzodiazepines - adverse effects
Benzodiazepines - therapeutic use
Body Mass Index
Chemistry, Pharmaceutical
Chronic Disease
Dose-Response Relationship, Drug
Female
Humans
Male
olanzapine
orally disintegrating tablets
Overweight - complications
Overweight - physiopathology
Overweight - prevention & control
Prospective Studies
Psychotic Disorders - complications
Psychotic Disorders - drug therapy
schizophrenia
Schizophrenia - complications
Schizophrenia - drug therapy
weight loss
Weight Loss - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To investigate the long‐term weight loss outcomes during usual clinical practice after switching from olanzapine standard oral tablet (SOT) to olanzapine orally disintegrating tablets (ODT). Method In this open‐label prospective study, 26 patients with schizophrenia who were clinically stable on olanzapine SOT treatment were switched to olanzapine ODT. All other aspects of treatment remained constant. Weight was recorded at 3, 6, and 12 months. Results Patients incurred an average weight loss of 2.7 ± 0.7 kg (p = 0.001) after switching patients from olanzapine SOT to olanzapine ODT at 12 months. Peak weight loss was observed at 6 months; however, significant weight loss was achieved as early as 3 months. The majority (81.9%) of patients lost weight, while 18.1% had no weight change or weight gain. Body mass index (BMI) significantly decreased by 1.0 ± 0.3 kg/m2 (p = 0.001). Interestingly, patients treated with higher doses of olanzapine (≥20 mg) incurred a greater weight loss of their body weight (5.6%), compared to those treated with lower doses (
ISSN:0885-6222
1099-1077
DOI:10.1002/hup.921